WO2021054533A3 - Composition pharmaceutique contenant de l'eficonazole stabilisée comprenant de l'acide sorbique en tant qu'acide - Google Patents

Composition pharmaceutique contenant de l'eficonazole stabilisée comprenant de l'acide sorbique en tant qu'acide Download PDF

Info

Publication number
WO2021054533A3
WO2021054533A3 PCT/KR2019/017069 KR2019017069W WO2021054533A3 WO 2021054533 A3 WO2021054533 A3 WO 2021054533A3 KR 2019017069 W KR2019017069 W KR 2019017069W WO 2021054533 A3 WO2021054533 A3 WO 2021054533A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
pharmaceutical composition
eficonazole
stabilized
containing pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2019/017069
Other languages
English (en)
Korean (ko)
Other versions
WO2021054533A2 (fr
Inventor
김범준
구교탄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biobelief Co Ltd
Original Assignee
Biobelief Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190125942A external-priority patent/KR20210032868A/ko
Application filed by Biobelief Co Ltd filed Critical Biobelief Co Ltd
Publication of WO2021054533A2 publication Critical patent/WO2021054533A2/fr
Publication of WO2021054533A3 publication Critical patent/WO2021054533A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour administration topique, qui se présente sous la forme d'une solution contenant de l'eficonazole comprenant de l'acide sorbique en tant qu'acide. La composition pharmaceutique de la présente invention présente une excellente stabilité physico-chimique.
PCT/KR2019/017069 2019-09-17 2019-12-05 Composition pharmaceutique contenant de l'eficonazole stabilisée comprenant de l'acide sorbique en tant qu'acide Ceased WO2021054533A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20190113969 2019-09-17
KR10-2019-0113969 2019-09-17
KR1020190125942A KR20210032868A (ko) 2019-09-17 2019-10-11 산으로서 소르빈산을 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR10-2019-0125942 2019-10-11

Publications (2)

Publication Number Publication Date
WO2021054533A2 WO2021054533A2 (fr) 2021-03-25
WO2021054533A3 true WO2021054533A3 (fr) 2021-05-14

Family

ID=74884652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/017069 Ceased WO2021054533A2 (fr) 2019-09-17 2019-12-05 Composition pharmaceutique contenant de l'eficonazole stabilisée comprenant de l'acide sorbique en tant qu'acide

Country Status (1)

Country Link
WO (1) WO2021054533A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317695A1 (en) * 2006-12-28 2010-12-16 Tomohiro Okumura Gel composition for treating mycosis
KR20160068812A (ko) * 2013-10-03 2016-06-15 다우 파마슈티컬 사이언시즈, 인코포레이티드 안정화된 에피나코나졸 조성물
KR20160087898A (ko) * 2013-11-22 2016-07-22 다우 파마슈티컬 사이언시즈, 인코포레이티드 항­감염 방법，조성물，및 장치
KR20170102013A (ko) * 2015-01-12 2017-09-06 아르노 테라퓨틱스 인코포레이티드 진균류 감염을 억제하기 위한 조성물 및 방법
US20190142800A1 (en) * 2016-06-13 2019-05-16 Vyome Therapeutics Limited Synergistic antifungal compositions and methods thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317695A1 (en) * 2006-12-28 2010-12-16 Tomohiro Okumura Gel composition for treating mycosis
KR20160068812A (ko) * 2013-10-03 2016-06-15 다우 파마슈티컬 사이언시즈, 인코포레이티드 안정화된 에피나코나졸 조성물
KR20160087898A (ko) * 2013-11-22 2016-07-22 다우 파마슈티컬 사이언시즈, 인코포레이티드 항­감염 방법，조성물，및 장치
KR20170102013A (ko) * 2015-01-12 2017-09-06 아르노 테라퓨틱스 인코포레이티드 진균류 감염을 억제하기 위한 조성물 및 방법
US20190142800A1 (en) * 2016-06-13 2019-05-16 Vyome Therapeutics Limited Synergistic antifungal compositions and methods thereof

Also Published As

Publication number Publication date
WO2021054533A2 (fr) 2021-03-25

Similar Documents

Publication Publication Date Title
ZA202206923B (en) New methylquinazolinone derivatives
EP4360707A3 (fr) Compositions pour le traitement de l'amyotrophie spinale
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EP4609866A3 (fr) Oxystérols et leurs procédés d'utilisation
PH12017500281B1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
EP4309735A3 (fr) Composition pharmaceutique de chlorhydrate de s-kétamine
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
EP4071149A3 (fr) Composés hétérocycliques et leurs utilisations
WO2011113855A3 (fr) Composition pharmaceutique pour le traitement d'une pression intraoculaire accrue
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
JO3430B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
EP4316591A3 (fr) Oxystérols et leurs procédés d'utilisation
AU2020231934A8 (en) Compounds useful in HIV therapy
EP4599887A8 (fr) Oxystérols et leurs procédés d'utilisation
EP4613741A3 (fr) Nanoparticules lipidiques pour l'administration d'oligonucléotides
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
HK1219222A1 (zh) 包含降血脂药的制剂
EP4559485A3 (fr) Formulation d'anticorps liquide
AU2019375825A8 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
PH12017502319A1 (en) Injectable pharmaceutical formulations of lefamulin
AU2020353055A8 (en) Antiviral pyrazolopyridinone compounds
AU2018264313A1 (en) Indolizine derivatives and application thereof in medicine
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
MX2021004379A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
WO2021054533A3 (fr) Composition pharmaceutique contenant de l'eficonazole stabilisée comprenant de l'acide sorbique en tant qu'acide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19946201

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19946201

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 13-09-2022)

122 Ep: pct application non-entry in european phase

Ref document number: 19946201

Country of ref document: EP

Kind code of ref document: A2